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Abstract
Background:  Cervical cancer (CC), a leading cause of cancer-related deaths in women
worldwide, has been causally linked to genital human papillomavirus (HPV) infection. Although a
host of genetic alterations have been identified, molecular basis of CC development is still poorly
understood.
Results: We examined the role of promoter hypermethylation, an epigenetic alteration that is
associated with the silencing tumor suppressor genes in human cancer, by studying 16 gene
promoters in 90 CC cases. We found a high frequency of promoter methylation in CDH1, DAPK,
RARB, and HIC1 genes. Correlation of promoter methylation with clinical characteristics and other
genetic changes revealed the following: a) overall promoter methylation was higher in more
advanced stage of the disease, b) promoter methylation of RARB and BRCA1 predicted worse
prognosis, and c) the HIC1  promoter methylation was frequently seen in association with
microsatellite instability. Promoter methylation was associated with gene silencing in CC cell lines.
Treatment with methylation or histone deacetylation-inhibiting agents resulted in profound
reactivation of gene expression.
Conclusions: These results may have implications in understanding the underlying epigenetic
mechanisms in CC development, provide prognostic indicators, and identify important gene targets
for treatment.
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Background
Carcinoma of cervix uteri (cervical cancer, CC) is a leading
cause of cancer-related mortality in women worldwide
[1,2]. CC arises by distinct morphologic changes from
normal epithelium and progresses to carcinoma through
a series of well-defined preinvasive lesions. Histologically,
CC presents as either squamous cell carcinoma (SCC) or
adenocarcinoma (AC) [3] with SCC predominating. Con-
verging evidence from epidemiological and molecular
studies suggests that infection of genital human papillo-
mavirus (HPV) is causally linked to the development of
CC [4]. Since only a small fraction of HPV-infected cervi-
cal intra-epithelial neoplastic (CIN) lesions progress to in-
vasive cancer, these studies further suggest that in addition
to HPV, other host genetic factors play a role in cervical
carcinogenesis [5]. A number of molecular studies have
identified genetic alterations in these two histologic types
of CC and at various stages of precursor lesions [6–8]. De-
spite this molecular characterization, the genetic basis of
CC initiation and progression is still very poorly under-
stood. Therefore, identification of the underlying genetic
changes may provide further insight into the molecular
basis of CC.
Epigenetic hypermethylation in the promoter regions of a
number of genes has been recognized as an important
change in the development of human cancer [9]. A grow-
ing number of cancer-related genes have been identified
to harbor methylation of cytosine residues in CpG-rich
promoter sequences. The pattern of such promoter meth-
ylation has been noted to be non-random in various tu-
mor types, while certain genes are commonly methylated
in diverse tumor types [10,11]. The extent of aberrant pro-
moter hypermethylation and its association with loss of
gene function in cancer suggests that CpG island methyl-
ation is an important mechanism in inactivating tumor
suppressor genes (TSGs).
The role of epigenetic gene inactivation in cervical tumor-
igenesis is poorly understood. A few previously published
reports on CC and its precursor lesions showed promoter
methylation of specific genes [12,13]. However, these
studies were limited by the small number of genes and tu-
mors examined. To investigate the role of promoter meth-
ylation in detail in cervical tumorigenesis, we evaluated
CpG methylation of 16 genes in 90 CC specimens and cell
lines. We found 86.6% of CC patients exhibiting promot-
er methylation. The CDH1, DAPK, RARB, and HIC1 gene
promoters were frequently methylated. Methylation sta-
tus was correlated with clinical and histologic characteris-
tics, and microsatellite instability (MSI). We also found
evidence that promoter methylation inactivates gene ex-
pression in CC and exposure to methylation and/or his-
tone deacetylase (HDAC)-inhibiting agents reactivate the
gene expression.
Results
CDH1, DAPK, RARB and HIC1 gene promoters are fre-
quently methylated in CC
We examined the status of promoter hypermethylation of
16 genes (CDH1, DAPK, RARB, HIC1, FHIT, RASSF1A,
APC, CDKN2A, MGMT, BRCA1, TP73, TIMP3, GSTP1,
MLH1, p14ARF, and RB1) in eight specimens of normal
cervical squamous epithelia and 90 CC specimens. Pro-
moter hypermethylation was not found in the DNA isolat-
ed from normal cervical smears for any of the tested genes.
However, hypermethylation was detected in one or more
genes in 79 of 90 (87.8%) CC specimens. The frequency
of promoter hypermethylation for individual genes was:
CDH1, 51.1%; DAPK, 43.3%; RARB, 33.3%; HIC1,
22.2%; FHIT, 11.1%; RASSF1A, 10%; APC, 10%;
CDKN2A, 8.9%; MGMT, 6.7%; BRCA1, 5.6%; TP73,
2.2%; TIMP3, 1.1%; GSTP1, 1.1%; and MLH1, 1.1% (Ta-
ble 1). The remaining two genes (p14 ARF and RB1) did
not show promoter methylation. Seventy-one of 82
(86.6%) primary tumors and 8 of 8 (100%) cell lines ex-
hibited methylation. Although the patterns are similar,
primary tumors had a higher frequency of methylation of
CDH1 and DAPK genes as compared to cell lines, while
RARB, HIC1, RASSF1A, MGMT, and TP73 genes had high-
er prevalence in cell lines as compared to primary tumors
(Table 1). A high frequency of promoter methylation was
detected in primary tumors for CDH1 (54.9%; 45 of 82
tumors) and DAPK (45.1%; 37 of 82 tumors). RARB
(29.3%) and HIC1 (18.3%) genes were less frequently
methylated in primary tumors. Other genes, FHIT (11%),
APC (11%), CDKN2A (8.5%), RASSF1A (7.3%), BRCA1
(6.1%), MGMT (4.9%), and TIMP3 (1.2%), were rarely
methylated in primary CC (Table 1, Fig. 1).
Figure 1
Methylation-specific PCR of CDH1, DAPK, RARB, and HIC1 
genes. U, unmethylated; M, methylated.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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Table 1: Frequency of promoter hypermethylation in cervical carcinoma
Gene
Speci-
men type
No. 
studied
Any 
gene
CDH1 DAPK RARB HIC1 FHIT RASSF1A APC CDKN2A MGMT BRCA1 TP73 TIMP3 GSTP1 MLH1
C o n t r o l s 8 00 0 0 000 00 0 0 0 0 0 0
CC cell 
lines
88  
(100)
1 
(12.5)
2 (25) 6 (75) 5 
(62.5)
1 
(12.5)
3 (37.5) 0 1 (12.5) 2 (25) 0 2 (25) 0 1 (12.5) 1 
(12.5)
Primary 
tumors
82 71 
(86.6)
45 
(54.9)
37 
(45.1)
24 
(29.3)
15 
(18.3)
9 (11) 6 (7.3) 9 (11) 7 (8.5) 4 (4.9) 5 (6.1) 0 1 (1.2) 0 0
Figures in parenthesis indicate percentage
Table 2: Correlation of promoter methylation with clinical and histologic parametrs, HPV status and microsatellite instability in CC 
patients
Methylated genes
Parameter Overall CDH1 DAPK RARB HIC1 FHIT RASSF1A APC CDKN2A MGMT BRCA1
Histology
SCC (N = 77) 66 45 36 24 12 9 5 5 6 4 3
AC (N = 5) 5 0 1 0 3 0 1 4 1 0 2
Significance P = 1.00 P = 0.02 P = 0.372 P = 0.315 P = 0.040 P = 1.00 P = 0.323 P = 0.0003 P = 0.367 P = 1.00 P = 0.028
Stage
I (N = 17) 10 6 5 3 5 0 4 2 2 0 0
II (N = 19) 19 13 12 5 3 3 2 2 1 0 2
III-IV (N = 46) 42 16 20 16 7 6 0 5 4 4 3
Significance P = 0.0005 P = 0.0005 P = 0.129 P = 0.394 P = 0.460 P = 0.279 P = 0.003 P = 1.00 P = 0.759 P = 0.395 P = 0.397
Size of tumor
1–5 cm (N = 32) 28 20 13 10 8 3 4 4 1 0 1
≥ 6 cm (N = 38) 34 21 19 13 6 4 1 3 4 2 2
Significance P = 1.000 P = 0.540 P = 0.433 P = 0.793 P = 0.337 P = 1.00 P = 0.171 P = 0.695 P = 0.366 P = 0.497 P = 1.000
Age (yrs)
≤ 40 (N = 32) 28 17 17 12 6 6 1 1 3 3 1
41–50 (N = 17) 12 8 5 5 3 0 2 0 1 1 1
51–60 (N = 13) 13 6 5 6 3 2 1 6 1 0 3
> 60 (N = 20) 18 14 10 1 3 1 2 2 2 0 0
Significance P = 0.113 P = 0.439 P = 0.400 P = 0.021 P = 0.956 P = 0.169 P = 0.600 P = 0.0004 P = 1.000 P = 0.467 P = 0.053
Clinical Outcome
Alive (N= 39) 30 18 19 8 7 3 5 4 2 0 0
DOC (N= 43) 41 27 18 16 8 6 1 5 5 4 5
Significance 0.015 P = 0.131 P = 0.533 P = 0.097 P = 0.939 P = 0.487 P = 0.097 P = 1.000 P = 0.436 P = 0.118 P = 0.056
Treatment response¶
CR (N= 21) 19 11 15 3 4 1 2 3 2 0 0
DOC/PR (N = 26) 24 15 10 12 4 3 1 4 3 2 2
Significance 1.000 0.716 0.024 0.020 1.000 0.617 0.579 1.000 1.000 0.495 0.495
HPV type
HPV 16 (N = 47) 42 27 24 15 9 6 4 5 3 3 2
HPV 18 (N = 6) 5 2 1 1 2 0 1 1 1 0 1
Multiple (N = 11) 8 7 3 2 1 0 0 2 2 0 1
Others (N = 16) 12 9 8 5 2 3 0 0 1 1 1
significance P = 0.543 P = 0.740 P = 0.280 P = 0.792 P = 0.560 P = 0.467 P = 0.365 P = 0.288 P = 0.327 P = 1.000 P = 0.412
MSI
MSS (N = 30) 26 20 17 4 2 3 1 2 5 4 2
MSI-L (N = 9) 9 6 4 2 1 2 1 0 1 0 2
MSI-H (N = 9) 8 2 3 3 4 0 1 3 1 0 1
Significance P = 0.516 P = 0.065 P = 0.513 P = 0.434 P = 0.023 P = 1.000 P = 0.313 P = 0.079 P = 1.000 P = 0.443 P = 0.266
P value corresponds to the P value from the Fisher's Exact test for the first two rows and for the P value from the Analysis of Variance for the last 
3 rows. ¶Only patients with at least 5 months follow-up and treatment were considered and patients with treatment unknown or no treatment 
were excluded. SCC, squamous cell carcinoma; AC, adenocarcinoma; MSS, microsatellite stable; MSI-L, microsatellite instability low; MSI-H, micro-
satellite instability high; DOC, died of cancer; PR, partial responseMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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Analyses of HPV and microsatellite instability
Eighty-six of 90 (95.6%) tumors were positive for HPV
DNA. The remaining four tumors were HPV negative.
HPV 16 alone or in combination with other HPV types
was found in 55 (61.1%). HPV 18 was found in eight
(8.9%) tumors, while other HPV types (20 different types)
in 23 (25.6%) tumors.
Of the 82 primary tumors studied for promoter methyla-
tion, 48 tumors were also examined for microsatellite in-
stability (MSI) using 49 di- or tetra-nucleotide markers
[14–17]. We found 9 of 48 (18.8%) tumors had MSI-H,
and 9 of 48 (18.8%) tumors exhibited MSI-L phenotype.
The remaining tumors did not show MSI (Table 2).
Promoter hypermethylation in relation to histological, 
clinical and genetic characteristics
To evaluate the relationship between promoter hyper-
methylation and clinico-pathologic features, as well as
other genetic changes, methylation status was correlated
with histology, age, stage and size of the tumor, clinical
outcome, HPV type, and microsatellite instability. Table 2
shows the results of univariate analyses examining the as-
sociations between methylation and these characteristics.
Although both squamous cell carcinoma (SCC; 85.7%)
and adenocarcinoma (AC; 100%) exhibited an overall
high rate of promoter methylation, we found statistically
significant differences in various genes in these two histo-
logic subsets (Table 2). Promoter methylation of the
CDH1, RARB, FHIT, and MGMT genes was noted only in
SCC, whereas the AC exhibited significantly higher fre-
quency of promoter methylation of HIC1 (60% in AC vs.
15.6% in SCC), APC (80% in AC vs. 6.5% in SCC), and
BRCA1 (40% in AC vs. 3.9% in SCC) (Table 2).
A significant correlation was observed between the overall
frequency of methylation and the tumor stage (P = 0.001).
Higher stage (stages II-IV) tumors exhibited an increased
overall frequency of promoter methylation (Table 2).
However, the differences were not statistically significant
when individual genes examined. On the other hand,
RASSF1A methylation was associated with low-grade tu-
mors (P = 0.003). Tumor size has no effect on the overall
frequency of methylation. Age also has no influence on
overall frequency of promoter methylation. However,
RARB gene was more frequently methylated in younger
patients (34.7% in below 50 years and 21.2% in above 50
years age) (P = 0.02). Promoter methylation of APC (2.0%
in patients below 50 years vs. 24.2% in patients above 50
years age) (P= 0.001) and BRCA1 (4.1% in below 50 years
and 9.1% in patients above 50 years) (P = 0.05) genes
were significantly higher in older patients.
In order to assess the prognostic role, we also correlated
treatment response and clinical outcome with promoter
methylation. The overall frequency of methylation was
higher in patients who died of cancer (DOC) (95.3%) as
compared to those who were alive with recurring disease
or complete remission (76.9%) (Table 2) (P = 0.015). Al-
though statistically not significant, all the patients whose
tumors showed promoter methylation of MGMT (4 tu-
mors) and BRCA1 (5 tumors) genes DOC within 1–21
months of follow-up after the initial diagnosis. Promoter
methylation of the remaining genes did not show such
differences in relation to the outcome. To assess the role
of radiation and/or chemotherapy treatment on outcome,
we correlated methylation with response in patients with
at least 5 months follow up after treatment. No significant
differences in the overall promoter methylation were
found in patients with complete remission (CR) com-
pared to patients who DOC or had only partial response
(PR). In this group, all the patients that showed methyla-
tion of MGMT and BRCA1 genes failed to respond to the
treatment suggesting promoter methylation of these genes
may be a bad prognostic indicator (Table 2). Promoter
methylation of RARB  gene was also predicted a worse
prognosis as 80% of the patients with methylation were
either DOC or only partial responders compared to only
20% patients with CR exhibited methylation of this gene
(Table 2).
Table 3 summarizes the results from multivariate Cox Sur-
vival models. Overall, after adjusting for age, treatment,
tumor size, stage and HPV type, neither total number of
methylated genes nor presence of methylation of each
specific gene were statistically significantly related to sur-
vival. However, methylation of 3 genes did suggest a dou-
bling (RASSF1A and MGMT) or tripling (BRCA1) of risk
compared to those who did not have these genes methyl-
ated. These differences were not statistically significant
due to small number of tumors analyzed and need to be
confirmed using a larger sample size.
Type of HPV infection had no association with the status
of promoter methylation (Table 2). Although the MSI
phenotype also had no significant correlation with overall
promoter methylation, the HIC1 (P = 0.02) and APC (P =
0.08) genes were frequently methylated in patients exhib-
iting MSI-H phenotype (Table 2).
CDH1 and RARB expression in CIN
To examine the role of CDH1 and RARB genes in CC pro-
gression, we carried out immunohistochemical analysis in
39 CIN specimens (Nine low-grade and 30 high-grade).
None of the low-grade CINs showed down-regulated ex-
pression, while only 2 of 30 (6.7%) showed absent or re-
duced expression suggesting that CDH1 inactivation is a
later event in CC development. The expression pattern of
RARB in normal epithelium is complex since the staining
intensities are highly variable between nuclear and cyto-Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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Table 3: Promter Hypermethylation and cervical cancer survival
Alive Dead Hazard Ratio§ 95%CI
Total loci 0 9 2 1.00 –
1 6 9 0.75 0.14–4.00
2 13 19 1.04 0.20–5.50
≥3 11 13 1.07 0.19–5.92
CDH1 + 18 27 0.69 0.29–1.63
-2 1 1 6 1 . 0 0 –
DAPK + 19 18 0.53 0.23–1.19
-2 0 2 5 1 . 0 0 –
RARB + 8 16 1.66 0.80–3.46
-3 1 2 7 1 . 0 0 –
HIC1 + 7 8 1.67 0.69–4.04
-3 2 3 5 1 . 0 0 –
FHIT + 3 6 1.18 0.38–3.66
-3 6 3 7 1 . 0 0 –
RASSF1A + 5 1 2.02 0.16–25.08
-3 4 4 2 1 . 0 0 –
APC + 4 5 0.70 0.21–2.41
-3 5 3 8 1 . 0 0 –
CDKN2A + 2 5 1.64 0.51–5.26
-3 7 3 8 1 . 0 0 –
MGMT + 0 4 2.30 0.46–11.45
-3 9 3 9 1 . 0 0 –
BRCA1 + 0 5 3.05 0.72–12.93
-3 9 3 8 1 . 0 0 –
Adjusted for age (continuous), treatment (3 groups), tumor size (binary), stage (3 groups) and HPV type (4 groups)
Figure 2
Immunohistochemical analysis of RARB gene expression in low- and high-grade CIN lesions from the same patient. A. Low-
grade CIN showing intense nuclear staining. B. High-grade CIN showing lack of nuclear expression.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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plasmic compartments. There was no normal epithelium
to evaluate the expression in most CIN cases studied.
However, all the cases that we evaluated for RARB immu-
noreactivity showed some positive mesenchymal cells.
We evaluated the intensity of nuclear staining in 34 cases
of paraffin-embedded tissues. One (11.1%) of the nine
low-grade CINs showed decreased nuclear expression,
whereas, 15 (60%) of 25 evaluable high-grade CIN le-
sions showed complete lack of nuclear expression (Fig. 2).
If confirmed, the down-regulated RARB expression in
high-grade CINs suggests that this occurs early in progres-
sion and plays a role in the development of CC.
Gene expression is down regulated by promoter hyper-
methylation and reactivated by demethylation
To examine the biological role of promoter methylation
in CC, we assessed the levels of mRNA by semi-quantita-
tive RT-PCR in eight cell lines and compared with the re-
spective control values obtained from the averages
calculated from 2 normal cervix after normalization
against ACTB. This analysis was performed on 7 genes
(CDH1,  DAPK,  RARB,  HIC1,  MGMT,  RASSF1A,  and
MLH1) that exhibited methylation in one or more cell
lines and primary tumors (Fig. 3). RARB gene showed ei-
ther complete absence of or down regulated expression in
all cell lines (6 methylated and 2 unmethylated). Of the
six cell lines with RARB gene methylated, three (HT-3,
MS751, and ME-180) exhibited reactivation upon treat-
ment with 5-Aza-2' deoxycytidine or n-butyrate alone or
the combination of the two. Three cell lines (C4-I, CaSki,
and SW756) that had promoter methylation of RARB did
not reactivate expression after treatment with these drugs
(Fig. 4). One of the two unmethylated cell lines also reac-
tivated the expression of RARB.
The CDH gene exhibited a complete absence of expression
in one cell line (SW756) that showed promoter hyper-
methylation and two other cell lines (C-33A and SiHa)
without evidence of methylation (Fig. 3). The SW756 cell
line with methylation and one of the two unmethylated
cell lines showed reactivated expression upon treatment
with 5-Aza-2' deoxycytidine or in combination with n-bu-
tyrate, but not with n-butyrate alone. The remaining five
cell lines neither showed evidence of decreased mRNA nor
any effect of demethylating or HDAC-inhibiting agents on
expression levels.
The DAPK gene showed a complete absence of expression
in five and down regulated expression in one of the 8 CC
cell lines studied (Fig. 3). Of the six cell lines with down
regulated expression, 2 had promoter methylation and 4
had unmethylated promoter of the DAPK  gene. Both
Figure 3
Semi-quantitative multiplex RT-PCR analysis of gene expres-
sion in CC cell lines. Genes are shown on left; cell lines are 
indicated on top. Empty arrows indicate the PCR product of 
actin gene used as control and filled arrowheads represent 
the indicated gene.
Figure 4
Effect of demethylation and acetylation on gene expression. 
Note the lack of reactivation of gene expression in C-4I in 
RARB gene. Lane 1, untreated; Lane 2, butyrate-treated; Lane 
3, 5-Aza-2' Deoxycytidine + butyrate treated, and Lane 4, 5-
Aza-2' Deoxycytidine-treated. Genes are shown on left; cell 
lines are indicated below; Empty arrows indicate the PCR 
product of actin gene used as control and filled arrowheads 
represent the indicated gene.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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methylated cell lines (HT-3 and SiHa) and three (C-33A,
MS751, and ME-180) of the four unmethylated cell lines
showed reactivation upon exposure to 5-Aza-2' deoxycyti-
dine or in combination with n-butyrate. One of the
unmethylated cell lines (SW756) that showed a complete
absence of expression did not reactivate after treatment.
The HIC1 gene was methylated in 5 of 8 cell lines. Three
of the methylated cell lines (C-4I, SiHa, and ME-180) and
one of the three unmethylated cell lines (MS751) showed
down regulated expression. Treatment of 5-Aza-2' deoxy-
cytidine or n-butyrate alone or the combination of both
activated gene expression in all the cell lines, whether or
not promoter had detectable methylation (Fig. 4).
The RASSF1A gene was methylated in 3 cell lines and all
three showed a complete lack of expression. None of the
unmethylated cell lines showed evidence of down-regu-
lated expression of RASSF1A  mRNA. Two of three cell
lines with RASSF1A methylation and complete lack of ex-
pression reactivated upon treatment with 5-Aza-2' deoxy-
cytidine alone or in combination with n-butyrate. One of
the methylated cell lines (HT-3), however, did not reacti-
vate gene expression after treatment. The unmethylated
cell lines showed normal expression and the treatment
had no effect on expression.
MGMT was methylated in two cell lines. One of the two
methylated cell lines (CaSki) showed a complete absence
of expression while the other methylated cell line
(SW756) showed normal levels of expression. Treatment
with demethylating and deacetylating inhibitor did not
activate the expression in any cell line regardless of pro-
moter methylation. MLH1 gene was methylated in one
cell line (SW756) but we found no evidence of down-reg-
ulated expression in this cell line (data not shown).
Discussion
Genetic alterations play an important role in the develop-
ment of CC [4,7,8]. Our extensive molecular analyses
identified a number of specific genetic changes in invasive
CC and its precursor lesions [6,14–19]. However, epige-
netic alteration in cervical tumorigenesis is not well char-
acterized [12,13]. In the present study, we identified an
overall methylation in 87.8% CC cases. Previous studies
by Dong et al (79%) and Virmani et al (72.4%) have also
reported a similar overall high frequency of promoter
methylation [12,13]. We identified promoter methylation
in >25% cases in CDH1, DAPK, and RARB genes, while it
was less frequent (10–25% cases) in HIC1,  FHIT,
RASSF1A, and APC genes in CC patients. The promoters
of CDKN2A, MGMT, BRCA1, TP73, TIMP3, GSTP1, and
MLH1 genes were rarely (<10% cases) methylated.
CDH1  is the most commonly methylated gene in the
present study showing promoter methylation in 51.1% of
CC cases. Dong and co-workers have shown earlier that
the CDH1 promoter is methylated in 28% of invasive CC
[13]. E-cadherin, CDH1, is a major adhesion component
of epithelial cells, which plays an important role as an in-
vasion suppressor gene. Loss of function of CDH1 gene
has been shown to occur in widespread of epithelial
tumor types by mutational or promoter hypermethylation
mechanisms [11,20]. We have also identified loss of ex-
pression of CDH1 gene in 37.5% of CC cell lines ana-
lyzed. Thus, these data suggest that inactivation of the
CDH1 gene by promoter methylation plays a major role
in CC tumorigenesis. However, our immunohistochemi-
cal analysis of E-cadherin protein showed no evidence of
decreased expression in precursor CIN lesions. Therefore,
these data indicate that the methylation of CDH1 gene is
a late event in the development of CC.
DAPK gene is methylated in 43.3% cases in the present
study. Dong and co-workers also previously showed
promoter methylation in 51% of CC [13]. DAPK is a pos-
itive mediator of the programmed cell death induced by
gamma-interferon [21]. Loss of DAPK expression has been
shown to occur in a number of human malignancies, pri-
marily by promoter hypermethylation [11]. It has also
been shown that loss of DAPK gene expression was asso-
ciated with aggressive and metastatic phenotype in many
tumor types [22]. In the present study, in addition to
showing high frequency of promoter methylation of
DAPK gene, we found a complete lack of expression in
two of the methylated cell lines and four of 6 unmethylat-
ed cell lines. Thus, our results suggest that loss of expres-
sion occurs in CC cell lines by mechanism other than
complete promoter methylation. Therefore, our data fur-
ther suggest a role for DAPK in CC tumorigenesis.
The third most commonly methylated gene in the present
study is RARB. A previous study also has reported promot-
er methylation in 33.3% of invasive CC, and 11% and
29% of low- and high-grade CIN lesions, respectively
[12]. These authors suggest that RARB methylation is an
early event in multistage cervical carcinogenesis. Our
semi-quantitative analysis of RARB gene expression by RT-
PCR showed down-regulated expression in all the eight
cell lines analyzed whether or not the promoter methylat-
ed (Fig. 3). In addition, our immunohistochemical analy-
sis of RARB showed lack of expression in 60% of high-
grade CINs. It has been reported that RARB  mRNA is
down regulated in a number of tumor types [23], includ-
ing cervical cancer [24]. Taken together, these data sup-
port the concept that RARB play an important role early in
cervical cancer progression. The direct role of RARB in reg-
ulating gene expression and its retinoid-mediated antipro-
liferative, differentiative, immuno-modulatory, andMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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apoptotic-inducing properties may offer a therapeutic tar-
get in the future for CC treatment [25].
As reported in a previous study, we also found promoter
methylation of HIC1 in 22.2% of CC [13]. HIC1 is a zinc
finger transcription factor that is transcriptionally silenced
by promoter methylation in several types of human can-
cer [26]. Heterozygous Hic1 mouse with promoter meth-
ylation of wild type allele develop carcinomas, sarcomas
and lymphomas, suggesting that this gene acts as a tumor
suppressor gene [27]. HIC1 gene was down regulated in
majority of the CC cell lines examined by us and this
down-regulated expression was reactivated upon treat-
ment with demethylating and HDAC-inhibiting agents.
These results support the tumor suppressor role of HIC1
and its inactivation by promoter methylation in CC may
be a critical epigenetic change in tumor development.
The present methylation profile of CC identified signifi-
cant differences in the methylated genes between SCC and
AC. We found that methylation of HIC1,  APC, and
BRACA1 genes was more common in AC while CDH1
promoter methylation was seen only in SCC. Such differ-
ences in the two major histologies have also been reported
previously for DAPK, HIC1, and APC genes [13]. Howev-
er, we found CDH1 promoter methylation restricted to
SCC in the present study, while Dong et al found methyl-
ation in both histological types [13]. This difference may
be due to small number of AC patients we studied. Dis-
tinct patterns of promoter methylation between SCC and
AC, however, suggest that epigenetic pathways of tumor
suppression may be different in these histologic subtypes.
Contrary to the previous reports, we found a low frequen-
cy of p16/CDKN2A  gene promoter methylation
[12,13,28,29]. The reason for these differences is currently
unclear.
Our statistical correlative analysis of promoter methyla-
tion with clinicopathologic parameters, HPV type, and
microsatellite instability identified significant associa-
tions. A most significant finding was that overall promot-
er hypermethylation is associated with the progression
and predicts significantly poor disease-free survival. This
was most evident in BRCA1 and MGMT genes, where all
the patients with promoter methylation were dead (Table
2). The multivariate Cox regression analysis showed that
promoter methylation is an independent predictor of out-
come for BRCA1 (3-fold risk) and MGMT (2.3 fold risk)
genes. Promoter methylation of cancer-related genes has
been reported to predict patient prognosis for a number of
genes [30,31]. BRCA1 plays a critical role in DNA repair
and recombination, cell cycle checkpoint control, and
transcription. This gene has been shown to be hypermeth-
ylated in tumors arising from breast-ovarian cancer syn-
drome [32]. Although we detected complete promoter
methylation of BRCA1 gene in only 6% of primary tu-
mors, other mechanisms that inactivate this gene might
exist. The present MSP data and its relation to poor
clinical outcome warrants a further study of BRCA1 role in
CC.  MGMT  gene encodes O(6)-methylguanine-DNA
methyltransferase and this enzyme effectively removes
DNA adducts formed by alkylating agents [33]. Epigenetic
gene silencing of MGMT confers enhanced sensitivity to
alkylating-based chemotherapy, and lack of methylation
associates with failure to respond to chemotherapy
[34,35]. On the contrary, all patients that had MGMT pro-
moter methylation were dead within 21 months of initial
diagnosis, which predicts a poor prognosis. A possible ex-
planation for this failure to respond may be that all the
four patients in the present study were treated only with
radiotherapy with or without combination of surgery. The
standard treatment for advanced-stage cervix cancer has
been the combination of radical surgery and radiotherapy
[36]. The utility of cytotoxic chemotherapy in patients
with advanced CC has been recognized recently [37].
Thus, the epigenetic gene silencing of MGMT, although in
a small proportion, may serve as indicator of responsive-
ness to treatment with chemotherapeutic drugs that cause
DNA adducts in CC.
Most patients in the present study population were treated
with traditional radiation and surgery treatment proto-
cols. To assess the impact of promoter methylation on
treatment, we compared the patients followed for more
than 5 months after treatment. This analysis suggests that
RARB methylation predict a worse prognosis (P = 0.02).
Twelve of the 15 (80%) patients with RARB methylation
were DOC or did not respond to the current treatment,
while only 3 of the 15 (20%) patients with RARB methyl-
ation exhibited complete response. Since RARB functions
as a tumor suppressor gene and its chemopreventive ef-
fects are purely based on retinoid induced reactivation,
the patients that received radiation therapy will have no
effect on these tumors. Our data, therefore, suggest that
the CC patients showing RARB  promoter methylation
may benefit from targeted chemopreventive treatment of
combination of retinoic acid, demethylating, and chro-
matin modifying agents that reactivate the gene expres-
sion. An understanding of the exact mechanisms of RARB
loss of function in CC is essential for such a strategy.
Microsatellite instability (MSI) is hallmark of mismatch
repair-deficient cancers, which has been observed in all
cancers arising from Hereditary Non-polyposis Colorectal
Cancer (HNPCC) syndrome, some sporadic colorectal
and other cancers [38]. MSI is generally associated with
germ-line mutations in one of two MMR genes, hMLH1
and hMSH2. Epigenetic inactivation of promoter hyper-
methylation of APC and HIC1 also results in MSI pheno-
type in sporadic colorectal cancers [39,40]. AccumulatingMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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evidence supports the view that promoter methylation of
mismatch repair genes may be related to MSI phenotype
[41,42]. A number of previous studies have shown the ex-
istence of MSI phenotype in CC [43,44]. In the present
study, we found that MSI-H occurs at an increased fre-
quency in tumors with HIC1 and APC promoter hyper-
methylation. Association of APC promoter methylation
with MSI phonotype has been previously reported in en-
dometrial cancer [45]. Although the significance of these
results is currently unclear, we believe that inactivation of
these genes by promoter methylation causes microsatel-
lite instability and may contribute to the development of
CC.
Aberrant promoter methylation changes that occur in can-
cer are associated with transcriptional repression and loss
of function of the methylated gene [9]. Since we found ev-
idence of down-regulated expression of several methylat-
ed genes in CC cell lines, we tested to see if this down-
regulation could be reactivated by methylation and
HDAC-inhibiting agents. Transcriptional silencing of
genes resulting from DNA hypermethylation of CpG is-
lands is reversed by treatment with the hypo-methylating
agent 5-aza-2'-deoxycytidine and HDAC-inhibiting agent
n-butyrate in a dose and duration-dependent manner. We
found that 5-Aza-2'-deoxycytidine treatment alone or in
combination with n-butyrate resulted in reactivation of
gene expression in most cell lines that showed promoter
methylation. In some cell lines, exposure to n-butyrate
alone has resulted in reactivation of the gene expression,
for example in HIC1 gene (Fig. 4). These data, therefore,
suggest that other epigenetic mechanisms involving de-
fects in chromatin modification factors such as acetylation
and methylation of histone proteins may also play role in
gene silencing. Thus, our data also suggest that epigenetic
changes that accompany methylation are common in CC
and play critical role in CC development.
Conclusions
The present study identified promoter methylation in a
number of genes in CC. The most frequently methylated
genes were CDH1, DAPK, RARB, and HIC1. We have also
shown that promoter methylation of these genes result in
transcriptional repression. Furthermore, RARB  gene ex-
pression is down regulated in high-grade CINs. These data
suggest that some of the methylated genes may play a role
early in the progression of cancer. Here we showed that
promoter methylation is associated with advanced stage
of the disease, RARB and BRCA1 promoter methylation
predict a worse prognosis, and the HIC1 and APC promot-
er methylation is frequently associated with MSI. This
knowledge of epigenetic changes in CC may have implica-
tions in our understanding of the role they play in CC de-
velopment. Particularly, if the present results are
replicated and identified in precancerous lesions, this may
be useful in predicting the high-risk lesions to progression
and serve as targets of treatment.
Methods
Patients, Tumor tissues, and cell lines
A total of 82 tumor biopsies derived from previously un-
treated primary invasive CCs and eight cell lines were
used. The tumor biopsies were ascertained from patients
evaluated at the Instituto Nacional de Cancerologia (San-
ta Fe de Bogota, Colombia) and from the Department of
the Obstetrics and Gynecology of Friedrich Schiller Uni-
versity, Jena, Germany after appropriate informed consent
and approval of protocols by institutional review boards.
The primary tumors were clinically classified as FIGO
stage IB (17 tumors), IIB (19 tumors), IIIB (43 tumors),
and IV (3 tumors). Histologically, 77 tumors were classi-
fied as squamous cell carcinoma (SCC) and five as aden-
ocarcinoma (AC). Clinical information such as age, stage
and size of the tumor, follow-up after treatment was col-
lected for all patients. Patient follow-up data was collected
from the review of institutional medical records, and by
contacting outside physicians and institutions. The follow
up ranged from 1–72 months. Thirty-nine cervical in-
traepithelial neoplastic lesions derived from 37 patients
were also obtained as formalin-fixed and paraffin-embed-
ded archival tissues from Columbia University and Insti-
tuto Nacional de Cancerologia (Santa Fe de Bogota,
Colombia). Eight normal cervical swabs, diagnosed on
Pap smear as normal squamous epithelium, were collect-
ed in phosphate buffer saline from the patients attending
Gynecology Clinic at the Columbia Presbyterian Medical
Center, New York after appropriate informed consent.
Cell pellets obtained from the swabs were used to isolate
DNA. CC cell lines SiHa, SW756, C-4I, Ca Ski, C-33A, HT-
3, MS751 and ME-180 were obtained from the American
Type Culture Collection (Manassas, VA), and grown in tis-
sue culture according to the supplier's recommendations.
Frozen tumor tissues or cell pellets were utilized for isolat-
ing DNA and/or RNA by standard methods.
Methylation Specific PCR (MSP)
Genomic DNA was treated with sodium bisulphite as pre-
viously described [46]. Placental DNA treated in vitro
with SssI methyltransferase (New England Biolabs, Bever-
ly, MA) and similarly treated normal lymphocyte DNA
were used as controls for methylated and unmethylated
templates, respectively. The primers used for amplifica-
tion of methylated and unmethylated promoters of genes
RARB, TIMP3, CDKN2A, p14ARF, MGMT, DAPK, CDH1,
GSTP1,  APC  promoter 1A, RB1,  MLH1,  TP73,  BRCA1,
FHIT, and HIC1 have been described previously http://
pathology2.jhu.edu/pancreas/prim0425.htm#MSP;
[32,47–49]. Methylated (MF and MR) and unmethylated
(UF and UR) primers for RASSF1A  promoter were de-
signed according to Herman et al [46] and as describedMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/24
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earlier [50]. PCR products were run on 2% agarose gels
and visualized after ethidium bromide staining. Purified
MSP products were sequenced in representative speci-
mens by direct sequencing to confirm the methylation
identified on agarose gels.
5-Aza-2' deoxycytidine and n-butyrate treatment, and 
analysis of gene expression
Cell lines were treated with demethylating agent 5-Aza-2'
deoxycytidine (Sigma) for five days at a concentration of
2 to 5 µM, HDAC-inhibiting agent n-butyrate at a final
concentration of 5 µM for the last 24 hours or a combina-
tion of both. Total RNA isolated from treated and untreat-
ed cell lines, and the total RNA and poly A+ RNA from
normal cervix obtained from Ambion (Austin, TX) was re-
verse transcribed using random primers and the Pro-STAR
first strand RT-PCR kit (Stratagene, La Jolla, CA). A semi-
quantitative analysis of gene expression was performed in
replicate experiments using 26–28 cycles of multiplex RT-
PCR with β-actin (ACTB) as control and gene specific
primers spanning at least 2 exons. The primers used for
CDH1, MGMT, MLH1, and RARB  have been described
earlier [50]. The gene primers used for DAPK  and
RASSF1A and their positions in respective cDNAs were:
DAPK-F  5'-CAGTTTGCGGTTGTGAAGAA-3' (403–422
bp)
DAPK-R  5'-CCTGCAACGAGTTCCAAGAT-3' (610–629
bp)
RASSF1A-F 5'- GACCTCTGTGGCGACTTCAT-3' (232–
251 bp, exon 1A)
RASSF1A-R 5'-GCTGTTGATCTGGGCATTGT-3' (461–480
bp)
The PCR products were run on 1.5% agarose gels, visual-
ized by ethidium bromide staining and quantitated using
the Kodak Digital Image Analysis System (Kodak, New
Haven, CT).
Microsatellite analysis
High-molecular weight DNA from frozen tumor and the
corresponding peripheral blood specimens was isolated
as previously described [14]. A panel of 49 sequence
tagged repeat polymorphic (STRP) (24 markers mapped
to chromosome 2q, nine on 5p, 11 on 6p, and five on
11q) markers, previously analyzed for LOH, was chosen
for scoring MSI [14–17]. The criterion for analysis and
classification of MSI has been described earlier [51,52].
Detection of HPV
PCR amplification with PGMY09/11 L1 consensus HPV
L1 primers followed by reverse line blot hybridization was
used to detect 38 genital HPV types as described earlier
[53,54]. Appropriate control experiments were set up us-
ing bulk master mix components to eliminate potential
contamination. Individual assay sensitivity was analyzed
by the use of serial dilutions of SiHa cell line crude cell di-
gest, targeting 104, 103, 102, 101, and 100 input copies of
HPV-16. A no template negative control was set up in all
experiments.
Immunohistochemistry
Four µ-thick sections were cut from paraffin-embedded
blocks and immuno-stained following deparaffinization
and antigen retrieval using citrate buffer at pH 6.0. Fol-
lowing incubation with antibodies against E-cadherin
(Dako, Carpinteria, CA) and RARB (NeoMarkers, Fre-
mont, CA), signal was detected with the Envision plus
(DAKO, Carpenteria, CA) system, using diaminobenzi-
dine as a chromogen. Tumors were considered positive for
E-cadherin when cells showed membrane staining. For
RARB, staining in normal epithelium either nuclear or cy-
toplasmic or both were considered positive. Normal
epithelium and mesenchymal cell expression were used as
internal controls.
Statistical Analysis
We first assessed associations between presence of pro-
moter methylation for each gene and various clinical, de-
mographic, and genetic characteristics using Chi-Square
test [55] and Fisher's Exact test (for small cell counts) [56].
Characteristics that we examined included: histology,
stage, tumor size, patient's age, clinical outcome, treat-
ment response, HPV type, and microsatellite instability.
Cox Proportional Hazard Models [57] were further ap-
plied to assess the relative hazard (risk) of dying associat-
ed with each methylated gene after adjusting for age,
treatment status, tumor size, stage, and HPV type.
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